Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20557488 | 0.78 | GPR119 (0.37) | RORCGPR119USP30NAMPTMAPK1 | |
| SCHEMBL20557469 | 0.78 | MEN1 (0.37) | RORCGPR119USP30 | |
| SCHEMBL20557719 | 0.76 | USP30 (0.35) | RORCGPR119USP30 | |
| SCHEMBL5185316 | 0.74 | POLB (0.46) | GPR119USP30NAMPTMAPK1 | |
| SCHEMBL29571353 | 0.74 | POLB (0.46) | GPR119USP30NAMPTMAPK1 | |
| SCHEMBL23257707 | 0.73 | NAMPT (0.54) | RORCGPR119NAMPTMAPK1KDM4E | |
| SCHEMBL4688868 | 0.73 | RORC (0.40) | RORCGPR119USP30NAMPTKDM4E | |
| SCHEMBL29457612 | 0.73 | NAMPT (0.54) | RORCGPR119NAMPTMAPK1KDM4E | |
| SCHEMBL21638874 | 0.73 | KMT2A (0.48) | GPR119USP30NAMPTMAPK1 | |
| SCHEMBL4143177 | 0.70 | POLB (0.52) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630111-B1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11046694-B2 | Compounds and methods for treating bacterial infections | ENTASIS THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3630111-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | Entasis Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| CN-110709081-A | Compounds and methods for treating bacterial infections | 恩塔西斯治疗公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2018208769-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | ENTASIS THERAPEUTICS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2009-01-15 | — | — | US | disclosed |
| US-7439253-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | NOVEXEL (FR) | 2008-10-21 | — | — | US | disclosed |
| US-7288549-B2 | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | AVENTIS PHARMA S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046694-B2 | Compounds and methods for treating bacterial infections | MRPL21, CFTR, C5 | RORC 994/4885GPR119 1377/4885USP30 4178/4885 |
| US-20200165251-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MRPL21, CFTR, C5 | RORC 994/4885GPR119 1377/4885USP30 4178/4885 |
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | GAA, ALPI, GANAB | RORC 1650/4885GPR119 4199/4885USP30 2221/4885 |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | RORC 1667/4885GPR119 4247/4885USP30 4084/4885 |
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | GAA, GANAB, ALPI | RORC 1381/4885GPR119 4127/4885USP30 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.